Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab

Abstract Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported in a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, a different sex hormonal profile, and intrinsic differences in local and systemic immune s...

Full description

Saved in:
Bibliographic Details
Main Authors: Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, Hideki Takeshita, Jose Carlos Tapia, María Natalia Gandur Quiroga, Elaine Lam, Deniz Tural, Lazar Popovic, Saul Campos-Gomez, Paolo Andrea Zucali, Augusto Mota, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Ondřej Fiala, Nuno Vau, Patrizia Giannatempo, Halima Abahssain, Andrea Benedetto Galosi, Giuseppe Badalamenti, Jindrich Kopecky, Aristotelis Bamias, Johannes Landmesser, Jawaher Ansari, Fabio Calabrò, Francesco Massari, Sebastiano Buti, Joaquim Bellmunt, Matteo Santoni
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Scientific Reports
Subjects:
Immunotherapy
NCT05290038
Pembrolizumab
Sex differences
Urothelial Cancer
Online Access:https://doi.org/10.1038/s41598-025-93094-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-93094-2

Similar Items